Calidi Biotherapeutics (CLDI) Convertible Debt (2024)
Calidi Biotherapeutics (CLDI) posted quarterly Convertible Debt of $1.8 million for Q3 2024, down 7.9% quarter-over-quarter from $1.9 million in Q2 2024.
Calidi Biotherapeutics (CLDI) Convertible Debt (2024) Analysis & Trends
Calidi Biotherapeutics' Convertible Debt history runs 1 years deep, the most recent figure standing at $1.8 million for Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.77 Bn | 131.91 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.36 Bn | 60.17 Bn | 1.37 Bn |
| 4 | Moderna | 59.60 Bn | 54.47 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - |
| 10 | Calidi Biotherapeutics | 1.96 Mn | -2.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 1.77 Mn |
| Jun 30, 2024 | 1.93 Mn |
| Mar 31, 2024 | 3.38 Mn |